Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Azn source : Www.biospace.com save search
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.04%
million series trials program
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.47%
H: 1.16%
C: -1.27%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.34%
H: 0.27%
C: -0.62%
children approved treatment for
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMajor achievements in 2023 lay the foundation for key upcoming milestones
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.75%
H: 0.04%
C: -0.1%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.08%
H: 0.33%
C: -0.53%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: -4.61%
H: 4.83%
C: 3.84%
business lay key financial results foundation
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
FUSN | $21.26 0.05% 0.05% 440K
|
Health Technology
|
| O: 96.99%
H: 1.19%
C: 1.05%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.38%
H: 0.46%
C: 0.4%
astrazeneca cancer treat acquire
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: 0.51%
H: 2.49%
C: 1.37%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.45%
H: 0.55%
C: -0.24%
lung test cancer risk study
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
Published: 2024-02-27 (Crawled : 15:30) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.72%
H: 2.54%
C: 2.54%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.01%
H: 0.79%
C: 0.6%
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Published: 2024-02-23 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.29%
H: 1.49%
C: 1.34%
show
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
lung license cancer cell application advanced
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence
Published: 2024-02-09 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.28%
H: 1.05%
C: -0.72%
bi-1206
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.24%
H: 0.07%
C: -0.1%
enhertu her2 granted review tumors positive
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Published: 2023-12-26 (Crawled : 10:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 54.84%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.01%
H: 0.0%
C: -0.33%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.32%
H: 0.21%
C: 0.0%
astrazeneca cell acquire therapy
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.03%
H: 1.08%
C: 0.73%
breast cancer trials plus initiated
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 5.03%
H: 0.0%
C: -3.82%
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.54%
H: 0.06%
C: -0.78%
vaccine astrazeneca positive acquire rsv potential
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.46%
H: 0.22%
C: -0.06%
ultomiris trial
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published: 2023-12-06 (Crawled : 22:00) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: 1.4%
H: 3.94%
C: 0.58%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.73%
H: 0.06%
C: -1.38%
america lung conference test cancer
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.23%
H: 1.45%
C: 0.97%
civo partnership pharma drug technology
AstraZeneca advances scientific leadership in hematology at ASH 2023
Published: 2023-11-29 (Crawled : 15:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.33%
H: 0.3%
C: -0.03%
astrazeneca
Pfizer Reports Third-Quarter 2023 Results
Published: 2023-10-31 (Crawled : 12:00) - biospace.com/
HLNCF | $3.94 -1.48% 1.2K
|
n/a
|
| O: 2.0%
H: 0.5%
C: 0.5%
HLN | $8.22 1.11% 0.0% 3.6M
|
n/a
|
| O: 0.75%
H: 0.74%
C: 0.12%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.7%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.87%
H: 1.77%
C: 0.91%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.65%
H: 2.78%
C: 2.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.08%
H: 0.41%
C: 0.38%
results
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-10-23 (Crawled : 20:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
enhertu her2 tumors trial phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.